

HEU-EFS

Harmonized Approach to Early
Feasibility Studies for Medical
Devices in the European Union

Disclaimer

Funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.

Challenge

Bringing medical technology innovations to patients in the EU has become increasingly long and difficult.



Rising R&D costs.



Ever-stricter EU regulations.



Lack of harmonised approaches in Member States for facilitating early evidence generations.



Uncertainty for innovators.



Decline in attractiveness of Europe.



European patients missing out on the latest medical technology innovations.

Needs



New approaches are needed to ensure patients get a timely access to their treatment and Europe remains at the forefront of innovation.

About EFS

Early Feasibility Studies (EFS) are small clinical studies designed to gain early, relevant insights into an innovative medical technology during the development process, before starting a larger clinical investigation, that would not be possible in a non-clinical setting.

EFS are a critical initial step of a longer chain of subsequent evidence-generation phase and provide a unique opportunity to:



1

Collect relevant **data**
at an early stage



2

Inform the
business case



3

**Maximize the chances to
develop innovative, cost-
effective, safe high-risk
medical technologies**

HEU-EFS approach



HEU-EFS will develop and validate a **robust, unified approach to allow early insights into technology evidence generation** and to make the EU a conducive environment to undertake EFS.

Acceptability will be driven by engagement of a wide network of stakeholders - universities, hospitals, contract research organizations, patient associations, health technology assessment agencies, MedTech companies and start-ups, regulatory authorities, notified bodies and professional associations.



HEU-EFS aim & objectives



HEU-EFS aims to develop an Harmonised Approach to EFS for Medical Devices in the European Union.

- 1** Conduct research and analysis on state of play of regulatory framework and characteristics and impacts of pre-market programs.
- 2** Build a sustainable network of stakeholders to promote the implementation of EFS in the EU.
- 3** Develop a sound, widely applicable and harmonised EU methodology and recommendations to uptake EFS.

- 4** Undertake pilot use cases to test the proposed methodological framework.
- 5** Develop instruments to monitor the performance of the EU EFS program.
- 6** Implement a dedicated, sustainable, open access informative online portal dedicated to EFS and disseminate the project results and recommendations.

Benefits



Patients with no or little treatment options access innovative technologies to improve prognosis & quality of life.

Payers and policymakers make evidence-based, informed investment decisions that meet patient needs and generate value for society.

Technology providers develop innovations that meet healthcare professional & patient needs.
Healthcare professionals deepen their clinical development excellence.



Patients



Health systems



Clinical & innovation excellence

HEU-EFS project facts



- 
- A photograph of a person wearing a light blue lab coat, viewed from the side, holding a tablet computer. The person's hand is positioned over the screen, suggesting they are interacting with it. The background is blurred, showing what appears to be a clinical or laboratory setting with soft lighting.
- 22 public and private consortium partners
 - 4-year project
 - €19 million grant from the Innovative Health Initiative
 - Coordinated by Bocconi University
 - Industrially led by Edwards Lifesciences

Consortium – public partners



Bocconi



Qurasoft



Consortium – private partners



Medtronic





www.heuefs.eu



[@HEU-EFS](#)



[@HEUEFS](#)



info@heuefs.eu

Thank you

This project is supported by the Innovative Health Initiative Joint Undertaking (JU) under grant agreement No 101112185. The JU receives support from the European Union's Horizon Europe research and innovation programme and life science industries represented by MedTech Europe, COCIR, EFPIA, Vaccines Europe and EuropaBio.



Co-funded by
the European Union